The Leading Community for Trusted Peptide Research & Insights
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.
Semaglutide is a GLP-1 receptor agonist with 94% sequence homology to human glucagon-like peptide-1. Used for weight management (Wegovy) and type 2 diabetes (Ozempic). Demonstrates significant effects on appetite regulation and glucose control.
Summary: Activates GLP-1 receptors in the brain and pancreas to suppress appetite, delay gastric emptying, and improve glucose-dependent insulin secretion. Mechanisms (reported/proposed across domains): Appetite & satiety • Activates GLP-1 receptors in hypothalamus and brainstem, stimulating satiety neurons (POMC/CART) and inhibiting hunger neurons (NPY/AgRP). • Reduces food cravings and hunger...
FDA Approved
Dose: 0.25–2.4 mg (titrated) · Route: Subcutaneous (SC) · Oral · Frequency: 1× weekly · Duration: 16–68+ weeks
Join a vibrant community sharing real peptide experiences, clinical research, and proven protocols. Data-backed, open, and censorship-free.